Early Access — free while we kick the tires
EdgarHawk

Sullivan Christopher Ryan

Chief Financial Officer

Officer

Latest: CFO selling · May 2026

1 filing analyzed · 1 company · Latest 2026-05-07

Companies

Company Buys Sells Direction
Avalo Therapeutics, Inc. AVTX 0 6 Net selling

Activity

May 2026
medium
Sell
47,000 shares
$948,722
Significance 6/10

CFO Sullivan Christopher Ryan sells nearly all holdings (5 tranches) while acquiring new shares in single transaction—net liquidation despite purchase.

Sullivan Christopher Ryan, the company's CFO, executed a complex set of trades on the same day: purchasing a large block of new shares while simultaneously selling nearly his entire existing position across five separate transactions. The net effect is a substantial reduction in total ownership despite the acquisition activity. This mixed transaction pattern occurred while the stock was trading at its 52-week high and has recently rallied sharply, which typically marks a natural exit point for insiders. The company remains unprofitable and faces structural financial headwinds, making the timing of this sale—at peak valuation—particularly notable. The magnitude of selling (roughly three times the purchase value) suggests the CFO is using the strength in the stock price to trim exposure rather than build conviction in a turnaround.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access